Timothy DeVere Cook - Dec 22, 2021 Form 3 Insider Report for Athenex, Inc. (ATNXQ)

Role
Chief Business and Commercial Officer, Proprietary Drugs Exhibit List: Exhibit 24.1 - Power of Attorney
Signature
/s/Steven Adams, Attorney-in-Fact
Stock symbol
ATNXQ
Transactions as of
Dec 22, 2021
Transactions value $
$0
Form type
3
Date filed
1/10/2022, 03:31 PM
Next filing
Mar 29, 2022

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding ATNXQ Stock Option (Right to Buy) Dec 22, 2021 Common Stock 70K $17.29 Direct F1
holding ATNXQ Stock Option (Right to Buy) Dec 22, 2021 Common Stock 30K $10.26 Direct F2
holding ATNXQ Stock Option (Right to Buy) Dec 22, 2021 Common Stock 9K $3.56 Direct F3
holding ATNXQ Restricted Stock Units Dec 22, 2021 Common Stock 9K Direct F4, F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This option vests in four equal annual installments beginning on August 17, 2019.
F2 This option vests in four equal annual installments beginning on August 27, 2021.
F3 This option vests in four equal annual installments beginning on September 16, 2022.
F4 The restricted stock units vest in four equal annual installments beginning on September 16, 2022.
F5 Each restricted stock unit represents a contingent right to receive one share of stock.

Remarks:

Chief Business and Commercial Officer, Proprietary Drugs Exhibit List: Exhibit 24.1 - Power of Attorney